Cutting edge: FcγRIII (CD16) and FcγRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. (Q45923021)
Jump to navigation
Jump to search
scientific article published on 12 November 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cutting edge: FcγRIII (CD16) and FcγRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. |
scientific article published on 12 November 2012 |
Statements
1 reference
Cutting edge: FcγRIII (CD16) and FcγRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. (English)
1 reference
Laurence Zitvogel
1 reference
David A Mancardi
1 reference
Lynn E Macdonald
1 reference
Bruno Iannascoli
1 reference
Andrew J Murphy
1 reference
Marc Daëron
1 reference
12 November 2012
1 reference
1 reference
189
1 reference
12
1 reference
5513-5517
1 reference
Identifiers
1 reference